SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

Augtyro

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market in the US (November 2023 for ROS1+ NSCLC; June 2024 for NTRK+ solid tumors), EU (conditional approval January 2025), China (May 2024), and Japan (November 2025 for NTRK+).
Why 4/10
No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for Augtyro in the next 12 months. It is already approved and commercialized across major markets (US, EU, China, Japan). The defining binary approvals already passed. ImpactScore is 4: the drug is approved with no pending regulatory binary, and for a ~$48B-revenue company it represents a very small commercial asset.
Actionable Insight NEUTRAL

With no imminent PDUFA or pivotal readout, Augtyro is not a binary catalyst stock for BMY. Watch for quarterly revenue trends in BMS earnings reports to see if global launches (EU, China, Japan) move the commercial needle from its current ~$50M annual run rate. The bigger BMY story is the Growth Portfolio vs Legacy Portfolio transition, with Eliquis patent cliff approaching in 2028.

Price Chart

Loading chart...

Executive Summary

Augtyro (repotrectinib) is a next-generation ROS1/TRK tyrosine kinase inhibitor approved in the US for ROS1-positive NSCLC (November 2023) and NTRK fusion-positive solid tumors (June 2024), with corresponding approvals in the EU, China, and Japan. It was acquired by Bristol-Myers Squibb (NYSE: BMY) via the $4.1B acquisition of Turning Point Therapeutics in 2022. Despite the approvals, the drug generated only $38M in global sales in FY2024, leading BMS to record a $1.4B impairment charge in Q4 2024 that it blamed on "evolving commercial opportunities." For BMY, a $60.52 stock with ~$48B in annual revenue, Augtyro is a very minor product within a vast portfolio and not a material share-price driver.

How It Works

A next-generation tyrosine kinase inhibitor taken orally that blocks specific proteins (ROS1, TRKA, TRKB, TRKC) that drive cancer growth in certain genetically defined tumors.

Trial Status

Two FDA approvals granted based on the registrational Phase 1/2 TRIDENT-1 trial (NCT03093116), a multicenter, single-arm, open-label study. The trial showed high objective response rates and durable responses in both ROS1-positive NSCLC and NTRK fusion-positive solid tumors. Updated TRIDENT-1 data were published in Nature Medicine in 2025 for the NTRK+ cohort and in the New England Journal of Medicine for the ROS1+ cohort. Post-marketing surveillance studies are ongoing in Japan for pediatric patients.

The Two-Sided Case

▲ Bull Case3
Augtyro is the only FDA-approved treatment for NTRK-positive tumors studied in both TKI-naive and TKI-pretreated patients across solid tumors, giving it a differentiated label.
The TRIDENT-1 trial data showed compelling efficacy: high objective response rates and durable responses in both ROS1+ NSCLC and NTRK+ solid tumors, including patients previously treated with other TKIs.
Growing global approvals (EU, China, Japan) open additional addressable markets. China NMPA approval in May 2024 and Japan MHLW approval in November 2025 could broaden the revenue base beyond the US.
▼ Bear Case5
BMS recorded a $1.4B impairment charge on Augtyro in Q4 2024, citing lower revised cash flow projections and an 'evolving commercial opportunity,' signaling weak commercial adoption.
Sales are modest at $38M in FY2024 for a drug that cost $4.1B to acquire through the Turning Point deal, implying a very poor return on investment to date.
The ROS1-positive NSCLC market is small (1-2% of NSCLC patients) and competitive, facing established rivals like Pfizer's Xalkori (crizotinib), Roche's Rozlytrek (entrectinib), Pfizer's Lorbrena (lorlatinib), and emerging agents like taletrectinib.
For BMY, a ~$48B+ revenue company, Augtyro is a negligible contributor. Even significant percentage sales growth would have minimal impact on the overall corporate financial picture.
The NTRK accelerated approval requires confirmatory trials, and failure to verify clinical benefit could lead to withdrawal of that indication.

Upcoming Catalysts

  • No imminent PDUFA date or pivotal readout is publicly scheduled for Augtyro. The drug is already approved in major markets, so the next catalysts would be commercial sales growth trajectory or potential label expansions into earlier treatment lines.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 15

Hover a chip for the title
1 en.wikipedia.org2 fda.gov3 fda.gov4 firstwordpharma.com5 businesswire.com6 news.bms.com7 ema.europa.eu8 nature.com9 nejm.org10 bms.com11 bms.com12 sec.gov13 english.nmpa.gov.cn14 pharmacompass.com15 marketscreener.com